The UCSF-GIVI CFAR Virology Core Laboratory provides laboratory services, consultation and training for multidisciplinary, translational research in order to advance collaborators'research programs in the prevention, treatment and understanding of HIV/AIDS. The laboratory typically supports 50 studies annually, ranging from small investigational pilot studies to large, multi-center clinical trials. Collectively, this work has significantly broadened our understanding of HIV disease pathogenesis, transmission and treatment.
The specific aims of the laboratory are to provide: 1. Service through development and implementation of molecular diagnostic assays and analysis tools under strict adherence to rigorous operational procedures and quality assurance programs. 2. Research through scientific leadership and laboratory resources to advance our understanding of ? HIV-1 transmission and correlates of protection that may lead to novel strategies for prevention. ? Viral replication in the context of latency and partial ARV drug suppression. ? The causes and consequences of ARV drug resistance. ? Host factors that modulate HIV replication and evolution. ? HIV replication and evolution in tissue compartments with a focus on transmission, antiretroviral drug resistance and disease progression. 3. Education and outreach through ? Mentoring and training of junior investigators and research scientists focused on translational research in local, national and international settings. ? Consultation with research collaborators, junior scientists and community members to assist in the interpretation and comprehension of virologic research findings. By collaborating with an increasingly strong network of multidisciplinary basic and clinical scientists, the Virology Core Laboratory is strategically and operationally poised to leverage CFAR funding to effectively support translational research, and advance our understanding of HIV transmission and disease pathogenesis, identify new and optimize the use of existing antiviral agents, and to guide vaccine design.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027763-19
Application #
8133769
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
19
Fiscal Year
2010
Total Cost
$289,030
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Tymejczyk, Olga; Brazier, Ellen; Yiannoutsos, Constantin et al. (2018) HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries. PLoS Med 15:e1002534
Sauceda, John A; Lisha, Nadra E; Neilands, Torsten B et al. (2018) Cognitive-affective depressive symptoms and substance use among Latino and non-Latino White patients in HIV care: an analysis of the CFAR network of integrated clinical systems cohort. J Behav Med :
Carrico, Adam W; Cherenack, Emily M; Roach, Margaret E et al. (2018) Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection. AIDS 32:767-771
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Mwimanzi, Francis; Toyoda, Mako; Mahiti, Macdonald et al. (2018) Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals. J Virol 92:
Krarup, A R; Abdel-Mohsen, M; Schleimann, M H et al. (2018) The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon. Mucosal Immunol 11:449-461
Shipley, Mackenzie M; Renner, Daniel W; Ott, Mariliis et al. (2018) Genome-Wide Surveillance of Genital Herpes Simplex Virus Type 1 From Multiple Anatomic Sites Over Time. J Infect Dis 218:595-605
Howe, Chanelle J; Dulin-Keita, Akilah; Cole, Stephen R et al. (2018) Evaluating the Population Impact on Racial/Ethnic Disparities in HIV in Adulthood of Intervening on Specific Targets: A Conceptual and Methodological Framework. Am J Epidemiol 187:316-325
Sanford, Ryan; Ances, Beau M; Meyerhoff, Dieter J et al. (2018) Longitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary Human Immunodeficiency Virus Infection. Clin Infect Dis 67:1697-1704

Showing the most recent 10 out of 1541 publications